A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...

Clinical services organizations help pharmaceutical manufacturers manage growing regulatory complexities, high development ...

Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.

The firm’s co-founders claim to be pursuing a “contrarian” approach, building a team versed in both computing and life sciences and concentrating resources on a smaller number of bets.

The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...

At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...

Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...

The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...

Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...

The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...

A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...

The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...